What changed in BIO-TECHNE Corp's latest annual report
In the year ended 30 Jun 2026, BIO-TECHNE Corp's revenue fell 0.4% to USD 1.22bn, from USD 1.22bn; cash and cash equivalents rose 63.2% to USD 264.71m, from USD 162.19m; shareholders' equity rose 9.9% to USD 2.11bn, from USD 1.92bn.
Year ended 30 Jun 2026. Source: 10-K filed 24 Aug 2026, read it on SEC EDGAR.
USD 1.22bn to USD 1.22bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 1.22bn | 1.22bn | Down 0.4% |
| Total assets | 2.56bn | 2.59bn | Up 1.1% |
| Cash and cash equivalents | 162.19m | 264.71m | Up 63.2% |
| Shareholders' equity | 1.92bn | 2.11bn | Up 9.9% |
Questions people ask
Did BIO-TECHNE Corp's revenue grow last year?
Revenue fell 0.4%, from USD 1.22bn to USD 1.22bn in the year ended 30 Jun 2026.
How much cash and debt does BIO-TECHNE Corp have?
At its latest year end (30 Jun 2026), BIO-TECHNE Corp reported cash and cash equivalents of USD 264.71m.
Where do these numbers come from?
From BIO-TECHNE Corp's own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with BIO-TECHNE Corp?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Biological Products, (No Diagnostic Substances) companies
- Amgen Inc.Net income up 88.5%
- Gilead Sciences, Inc.Net income up 1672.9%
- Moderna, Inc.Revenue down 39.9%
- Revolution Medicines, Inc.Total liabilities up 146.7%
- Biogen Inc.Net income down 20.8%
- Exelixis IncCash and cash equivalents up 122%
- Neurocrine Biosciences IncCash and cash equivalents up 206%
- Halozyme Therapeutics, Inc.Shareholders' equity down 86.6%